Mapatumumab

Mapatumumab (HGS-ETR1) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) . Mapatumumab can be used for the research of cancer[1].

Product Specifications

CAS Number

[658052-09-6]

Product Name Alternative

HGS-ETR1; Anti-Human TNFRSF10A Recombinant Antibody

UNSPSC

12352203

Target

Others

Type

Inhibitory Antibodies

Related Pathways

Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/mapatumumab.html

Purity

97.85

Solubility

10 mM in DMSO

Smiles

[Mapatumumab]

Molecular Weight

(143.52 kDa)

References & Citations

[1]Smith MA, et al. Initial testing (stage 1) of mapatumumab (HGS-ETR1) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010 Feb;54 (2) :307-10.|[2]Ahmed SM, et al. Synergistic induction of apoptosis by mapatumumab and anthracyclines in human bladder cancer cells. Oncol Rep. 2015 Feb;33 (2) :566-72.|[3]Marini P, et al. Combination of the pro-apoptotic TRAIL-receptor antibody mapatumumab with ionizing radiation strongly increases long-term tumor control under ambient and hypoxic conditions. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75 (1) :198-202.